Immuneering Corporation Completes $25 Million Private Placement
Immuneering Corporation (NASDAQ: IMRX), a clinical-stage oncology company dedicated to improving the lives of cancer patients, has announced the successful closing of its recent private placement. This transaction has secured approximately $25 million in gross proceeds, aimed at advancing its research and development efforts.
Details of the Private Placement
In this strategic move, Immuneering issued a total of 6,329,113 unregistered shares of its Class A common stock at a price of $3.95 per share. For specific investors, pre-funded warrants that allow the purchase of Class A common stock were also offered. Additionally, investors received accompanying purchase warrants to acquire an aggregate of 2,848,096 shares at an exercise price of $5.50 per share. Notably, these warrants are valid for a period of five years once registered for resale.
Transaction Overview
This private placement was executed with a select group of institutional and accredited investors, and paramount registration rights were granted to them as part of the agreement. It is worth noting that the securities involved have not been registered under the Securities Act of 1933 or applicable state laws, therefore the reoffering, or resale within the United States is governed by specific regulatory exemptions.
Role of Financial Advisors
Leerink Partners provided financial advisory services during this private placement, guiding Immuneering through the complexities of capital raising in the current market environment.
About Immuneering Corporation
Immuneering is at the forefront of developing novel cancer therapies known as Deep Cyclic Inhibitors. Their lead candidate, atebimetinib (IMM-1-104), represents an innovative treatment option designed to enhance the durability and tolerability of cancer therapies, focusing on MAPK pathway-driven tumors, including pancreatic cancers. Currently, this promising drug is undergoing a Phase 2a trial, targeting advanced solid tumors.
Future Directions
The company remains optimistic about its ongoing clinical trials and pipeline of early-stage programs. As they journey to bring impactful therapies to market, the recent funding will play a crucial role in propelling their research forward. They continue to explore unique treatment avenues that hold the potential to change the prognosis for many cancer patients.
Investor and Media Contacts
For investors seeking more information about this financing round and Immuneering’s upcoming initiatives, Laurence Watts is the point of contact at 619-916-7620. Media inquiries should be directed to Gina Nugent via email at gina.nugent.external@immuneering.com.
Frequently Asked Questions
What was the purpose of the $25 million private placement?
The $25 million raised through the private placement aims to support the development of innovative cancer therapies and ongoing clinical trials.
Who were the investors involved in this private placement?
Top-tier institutional and accredited investors were involved in this private placement, which reflects the strong confidence in Immuneering's potential.
What is atebimetinib (IMM-1-104)?
Atebimetinib is Immuneering’s lead product candidate, designed as a Deep Cyclic Inhibitor that targets MEK and aims to treat MAPK pathway-driven tumors.
How does the private placement affect future funding?
The funds generated from this private placement will facilitate further research and development, potentially reducing the need for additional immediate funding.
What is the significance of the warrants issued?
The accompanying purchase warrants offer investors an opportunity to further invest in Immuneering’s future growth, at an established price, representing a vote of confidence in the company's strategy.
